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SUMMARY
Limited prior evidence suggests that 5¢-nucleotidase, an ecto-
enzyme principally located in the Malpighian tubules of the
tick Rhipicephalus (Boophilus) microplus, could be an
effective antigen in an anti-tick vaccine. To assess this,
recombinant 5¢-nucleotidase was expressed in Escherichia
coli and used in vaccination trials with both sheep and
cattle. Vaccinated sheep were challenged with freshly
moulted adult ticks. Those with high titres of anti-nucleotid-
ase antibodies showed significant protection against tick
infestation, although protection was less than that found
with the previously characterized antigen, Bm86. Cattle were
vaccinated, in separate groups, with 5¢-nucleotidase, Bm86
and both antigens combined. Cattle, as the natural host,
were challenged with larval ticks. Although Bm86 showed
typical efficacy, no significant protection was seen in cattle
vaccinated with 5¢-nucleotidase. Cattle receiving a dual
antigen formulation were no better protected than those
receiving Bm86 alone. One possible reason for the difference
between host species, namely antibody titre, was examined
and shown to be an unlikely explanation. This demonstrates
a limitation of using a model host like sheep in vaccine
studies.
Keywords antigen, Boophilus microplus, nucleotidase,
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INTRODUCTION
One of the major stumbling blocks in the development of
anti-tick vaccines, as with other anti-parasite vaccines, is
the identification of effective antigens (1). For ticks, an
existing efficacious antigen, Bm86, is the basis of two
commercial vaccines, TickGARD Plus and Gavac Plus (1)
directed against the cattle tick Rhipicephalus (Boophilus)
microplus. Unless antigens yet to be discovered have effi-
cacy as good as or better than Bm86, it is likely that addi-
tional antigens will be primarily of interest in dual antigen
vaccine formulations aimed at further enhancing efficacy
or duration of protection. Yet, the ability of antigen cock-
tails to increase vaccine efficacy has received little experi-
mental examination and results have been equivocal (2).
The 5¢-nucleotidase from R. (Boophilus) microplus
would seem to have potential in the ‘concealed antigen’
approach to vaccination (3). The purification and charac-
terization of the native protein have been previously
reported (4,5). Among the characteristics likely to be of
importance for ‘concealed antigens’ are accessibility to
antibody ingested during tick feeding and a physiological
function of importance to the tick. Ideally too, one would
expect limited functional redundancy, that is, the antigen
should not have a large number of immunologically differ-
ent variants capable of performing the same physiological
function. The 5¢-nucleotidases are ectoenzymes commonly
used as markers for cell plasma membranes. The tick
enzyme, like the protective R. (Boophilus) microplus anti-
gen Bm86 (6), is bound by a glycosyl phosphatidylinositol
(GPI) anchor to the membrane. In R. (Boophilus) micro-
plus, the enzyme appears to be abundant on the surface of
cells lining the Malpighian tubules (7) and hence poten-
tially accessible to antibodies. It is known that antibody
can persist for long periods in the tick gut and that undi-
gested haemoglobin, and hence presumably other proteins,
can pass through the tick gut and be excreted (8).
Evidence from Southern blots suggests that while there is
more than one nucleotidase gene in R. (Boophilus)
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unusual, in that it degrades not only nucleotide mono-
phosphates to nucleosides but also the di- and triphos-
phates (4). These activities and the location of the enzyme
suggest a role in purine salvage (7) although this has not
been clearly established. The importance of purine salvage
to ticks is suggested by the fact that ingestion of allopuri-
nol in an in vitro feeding system increased mortality (7).
Allopurinol is an inhibitor of hypoxanthine guanine phos-
phoribosyl transferase, a component of the purine salvage
pathway.
However, there has been virtually no examination of
5¢-nucleotidase as an antigen. Purification of the native
enzyme from semi-engorged female ticks gave amounts of
protein too low for convincing vaccination trials in cattle
(4). Early attempts to produce a recombinant form of the
enzyme in Escherichia coli yielded large but incomplete
fragments of the protein with variable C-terminal trunca-
tions (9). It was shown, however, that antibodies to this
expressed protein as well as antibodies raised to the enzy-
matically active, baculovirus-expressed protein reacted with
native tick protein using Western blots and immuno-
fluorescent localization on tick organs (7). The E. coli-
expressed fragment was trialled in combination with Bm86
in a cattle vaccination experiment. The results suggested a
slight improvement in efficacy, although the animal num-
bers were too small and the effect too slight to show
statistical significance (10).
Support for the use of 5¢-nucleotidase as an antigen
came from Ixodes scapularis (11). Using an expression
library constructed using an I. scapularis cell line, mice
were vaccinated and challenged with a tick infestation.
Iteration of the process identified a number of efficacious
genes, one of the best being 4F8, a fragment of 316 amino
acids identified as a 5¢-nucleotidase. This fragment, how-
ever, has only 18% identity with the 5¢-nucleotidase from
R. (Boophilus) microplus, suggesting that the two proteins
are only distantly related.
The primary objective of current research therefore
was to assess the potential of 5¢-nucleotidase both alone
and in combination with Bm86 as antigens to protect
ruminants against tick challenge. This was performed
using two experimental hosts, sheep and cattle. Sheep
can be a useful host in vaccination trials (12,13).
Although larval attachment and development can be
problematic, freshly moulted adult ticks attach readily,
engorge and lay eggs normally (12). Whether the two
hosts are equivalent, however, is an unresolved question.
It was noticed, using Bm86 as an antigen, that vaccine
efficacy in sheep was much higher than in cattle (12,14).
Recombinant 5¢-nucleotidase was therefore assessed in
both sheep and cattle to see if the results obtained with
Bm86 were unique to that antigen or were also observed
with a second antigen.
MATERIALS AND METHODS
Materials
Parasite RNA extraction and cDNA synthesis
Rhipicephalus (Boophilus) microplus (non-resistant field
strain (NRFS)) ticks were supplied by Queensland Pri-
mary Industries and Fisheries (QPIF), Yeerongpilly. Total
RNA was prepared from R. (Boophilus) microplus using
Trizol Reagent as per the manufacturer’s recommendations
(Invitrogen; Groningen, The Netherlands). For cDNA syn-
thesis, 1 lg of total RNA was reverse transcribed in a
20 lL reaction mix using 0Æ5 lg oligo dT12–18 primer and
200 U Superscript III (Invitrogen) at 50 C for 60 min.
Oligonucleotides Nucleotid-F 5¢GAATTCAACCGACT-
TCACGGCGACAG and Nucleotid-R 5¢ GCGGCCGC-
GCAAGCATCCGAAGCCTGG were used to amplify the
open reading frame of 5¢-nucleotidase, which was cloned
into the pCR2.1 TA vector (Invitrogen) and sequenced.
The cDNA was subsequently sub-cloned into the pQE31
expression vector (QIAGEN, Valencia, California, USA) in
frame with the N-terminal Hexa-His tag. The Bm86 gene
was amplified using primers Bm86-Y 5¢GCGGCCGCA-
CTTGACTTTCCAGGATC and Bm86-Z 5¢GAATTCAG-
AATCCATTTGCTCTGAC and cloned into the pCR2.1
TA vector and sequenced. The cDNA was subsequently
cloned into pPICZaC in frame with sequence encoding the
signal sequence. Sequences were aligned using the National
Centre for Biotechnology Information (NCBI) pairwise
Blast server.
Isolation of antigens
The recombinant R. (Boophilus) microplus 5¢-nucleotidase
protein was produced in E. coli using the expression vector
noted above. The recombinant protein was purified from
E. coli inclusion bodies using Ni-NTA affinity chromato-
graphy (QIAGEN) following the manufacturer’s recom-
mendations. Following purification, the 5¢-nucleotidase
protein was diluted to 1 mg⁄mL and added slowly to
buffer (20 mM Tris, 3 M urea, 500 mM NaCl, 1 mM EDTA,
1m M reduced glutathione, 0Æ2m M oxidized glutathione,
0Æ5 M arginine hydrochloride, 0Æ01% Tween 20) to promote
refolding of the protein.
The Pichia protein expression system was purchased
from Invitrogen. Recombinant Bm86 was expressed in
Pichia following the manufacturer’s recommendations. The
Pichia strain, KM71H, was transformed with the
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method as detailed in the manufacturer’s protocol. Clones
were analysed by PCR for integration of the Bm86 cDNA.
Starter cultures were grown in buffered minimal glycerol
containing histidine (BMGH) media until OD >2 then
changed to buffered minimal methanol containing histidine
(BMMH) and incubated at 28 C with shaking. Methanol
was added daily for 4 days to induce and maintain recom-
binant protein expression. On the fourth day, the culture
was centrifuged at 2000 g for 10 min and the supernatant
collected. The supernatant was further clarified by centrifu-
gation (6000 g,4  C for 30 min) and 1 mM PMSF added.
The supernatant was then further clarified by filtration
through a series of 5, 2 and 0Æ45 lm filters.
After final clarification, the supernatant volume was
reduced using a stirred cell apparatus fitted with a 50 kDa
cutoff filter to a final volume of approximately 50 mL.
This solution was buffer exchanged for ConA affinity
purification (10 mM Tris, 0Æ15 M NaCl, 1 mM CaCl2,1m M
MnCl2,p H7 Æ5). Affinity purification was achieved using
ConA Sepharose (Pharmacia, Uppsala, Sweden). After
equilibration of the column with the above buffer, the
sample was loaded onto the column at a flow rate of 0Æ5
mL⁄min. The column was washed until the A280 returned
to baseline. Bound protein was eluted from the column
after a 1 h incubation with elution buffer (10 mM Tris,
0Æ5 M NaCl, 0Æ5 M a-methyl-D-mannoside, 1 mM CaCl2,
1m M MnCl2,p H7 Æ5). Eluted protein was buffer
exchanged to PBS.
Analysis of 5¢-nucleotidase and Bm86 protein expression
and the Ni-NTA and ConA affinity chromatography were
performed on standard SDS-PAGE gradient gels (15) and
stained with silver (16). The protein concentrations of the
purified recombinant proteins were determined using
the BCA protein assay (Pierce, Rockford, IL) according to
the manufacturer’s instructions. Amino terminal sequenc-
ing using an Applied Biosystems 492–01 HT protein
sequencer (Foster City, CA, USA) validated the amino
termini of both recombinant proteins.
Vaccination of sheep and parasite challenge
Sheep vaccinations were conducted in Border Leicester
crossbred wethers. Each antigen was used to vaccinate six
sheep, three using ISA50 as adjuvant and three with
ISA773 (Seppic). Vaccines were prepared according to the
manufacturer’s instructions, with 80 lg of the relevant
antigen per injection. Two control groups received adju-
vant alone.
Animals were given three intramuscular injections each
1 month apart with tick challenge occurring 2 weeks
following the third vaccination. Blood samples from the
jugular vein were collected at the time of each vaccination,
at tick challenge and at completion of the trial.
For the tick challenge, engorged nymphs of R. (Boophilus)
microplus were picked off previously unexposed Bos taurus
donor cattle, each infested with 30 000 larvae of the acari-
cide-susceptible NRF strain, purchased from QPIF. Nymphs
were held in a humidified incubator until adults emerged.
Sheep were prepared for tick challenge by closely crop-
ping the wool along the dorsal line and gluing 2 cm inter-
nal diameter aluminium rings to shaved skin. Duplicate
rings were used on each sheep. Each ring was infested with
10 female and 5 male newly emerged adult ticks, then
covered with a gauze lid. Following engorgement of the
adult females (7 days), ticks were collected and weighed.
All female ticks surviving to engorgement were incubated
to assess their capacity for egg laying.
Vaccination of cattle and parasite challenge
The cattle used were B. taurus (Hereford · Angus) heifers,
9 months old, with no prior exposure to R. (Boophilus)
microplus. Cattle were divided into three experimental
groups, each containing four animals, and were vaccinated
intramuscularly three times at monthly intervals, each with
100 lg of antigen, either Bm86 or nucleotidase. An addi-
tional group received a combination of the two proteins,
using 100 lg of each. Each antigen preparation was for-
mulated in a two component adjuvant. Half of the antigen
was formulated in ISA50 in the usual manner, while the
other half was formulated in 10 mg⁄mL QuilA. The final
vaccine was prepared by mixing nine volumes of ISA50
formulation with one volume of QuilA. Four control cattle
received adjuvant alone. Blood was sampled from the jug-
ular vein at six time points: at the time of each vaccina-
tion, before larval challenge, on day 19 of the infestation,
that is just before the engorgement of the first adult ticks
and on termination of the experiment.
Cattle were infested daily with 1000 tick larvae for
21 days, beginning 1 week following the third vaccination.
After the last infestation, cattle were moved into individual
moated pens and for the following 3 weeks, all engorged
adult female ticks dropping daily from the host were
collected, counted, weighed and visually examined for dam-
age. The results listed in Table 1 are the means of the data
for 18 individual days. On days 2 and 3, 6–10 and 14 of this
collection period, a sample of 50 females were weighed and
incubated to assess egg laying capacity. Reproductive
potential was calculated as the product of the mean num-
ber of ticks engorging per day, their weight and their fecun-
dity. Effectively it measures the mass of eggs laid by the
female ticks engorging from an infestation of 1000 larvae.
Statistical analyses were performed using Sigma Stat.
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Antibody titres were measured in serum against the relevant
antigen using ELISA (17,18). Briefly, antigen was coated on
wells of ELISA plates at a concentration of 1 lg⁄mL, then
overlayed with serial 2-fold dilutions of sheep or bovine sera
starting at an initial dilution of 1 in 1000. Peroxidase-cou-
pled rabbit anti-ovine IgG and ovine anti-bovine IgG were
used as second antibodies at a dilution of 1 in 1000. A pool
of sera from a sample taken prior to tick challenge and at
maximum antibody titres was used as an internal standard
in all ELISA assays, while pre-vaccination sera acted as
negative controls on all plates.
A series of assays to compare ovine and bovine anti-
nucleotidase titres were performed in an identical way,
with the substitution of peroxidase-coupled protein G
(Thermo Scientific, Waltham, MA, USA) as the detection
reagent. Dilutions used were 1 in 500, 1000 and 2000 of a
1m g⁄mL solution prepared according to the manufac-
turer’s instructions.
The ability of ovine IgG to compete with bovine IgG in
binding to nucleotidase on an ELISA plate was examined
by preparing serial 2-fold dilutions from 1 in 2000 to 1 in
512 000 of the standard bovine anti-nucleotidase pool in
the presence of a 1 in 2000 dilution of the ovine reference
pool. The same bovine dilution series was also prepared in
a 1 in 4000 dilution of the ovine serum, and in increasing
dilutions of the ovine serum to a maximum of 1 in 64 000.
ELISA assays were conducted as usual, with peroxidase-
coupled ovine anti-bovine IgG as a detection reagent. To
minimize and chance that the ovine anti-bovine IgG detec-
tion reagent would react with ovine IgG bound to the
ELISA plate, the second antibody was diluted in 1 in 1000
normal ovine serum.
RESULTS
Preparation of 5¢-nucleotidase and Bm86
The 5¢-nucleotidase and Bm86 cDNAs were derived from
the NRFS tick isolate, whereas the original proteins and
cDNA sequences were from the Yeerongpilly or Y iso-
late. The 5¢-nucleotidase sequence, however, showed only
two amino acid substitutions, one conservative. The
Bm86 sequence contained 14 amino acid changes distrib-
uted through the coding sequence, a variation of 2Æ5%.
This is typical of the allelic variation seen within this
protein in Australia (14). The recombinant proteins were
purified as detailed in Materials and methods section
and analysed by SDS-PAGE. The sizes of the recombi-
nant proteins were approximately 65 and 100 kDa for
5¢-nucleotidase and Bm86 respectively. N-terminal amino
acid sequencing of the purified proteins confirmed their
identity.
Table 1 Vaccination of cattle with recombinant 5¢-nucleotidase and Bm86 separately and as a dual antigen vaccine
Antigen Animal Mean tick no. Mean wt. (mg) Fecundity Reproductive potential
5¢-Nucleotidase 1 316 € 94 265 € 25 0Æ54 € 0Æ04 45Æ2
2 210 € 86 258 € 17 0Æ52 € 0Æ04 28Æ2
3 272 € 104 233 € 30 0Æ36 € 0Æ18 22Æ8
4 358 € 137 260 € 29 0Æ51 € 0Æ04 47Æ5
Mean 289 € 63 254 € 14 0Æ48 € 0Æ08 35Æ9€1 2 Æ3
Bm86 5 142 € 45 183 € 16 0Æ13 € 0Æ05 3Æ4
6 160 € 56 186 € 9 0Æ32 € 0Æ06 9Æ5
7 175 € 53 194 € 15 0Æ30 € 0Æ08 10Æ2
8 88 € 26 156 € 27 0Æ17 € 0Æ05 2Æ3
Mean 141 € 38** 180 € 17** 0Æ23 € 0Æ09** 6Æ4€4 Æ1**
Dual antigen 9 224 € 67 192 € 12 0Æ32 € 0Æ07 13Æ8
10 154 € 42 182 € 12 0Æ21 € 0Æ11 5Æ9
11 198 € 69 193 € 7 0Æ29 € 0Æ13 11Æ1
12 221 € 74 180 € 12 0Æ31 € 0Æ15 12Æ3
Mean 199 € 32* 187 € 7** 0Æ28 € 0Æ05** 10Æ8€3 Æ4**
Control 13 256 € 119 234 € 24 0Æ52 € 0Æ03 31Æ2
14 357 € 107 246 € 23 0Æ52 € 0Æ05 45Æ7
15 234 € 102 267 € 27 0Æ49 € 0Æ05 30Æ6
16 277 € 56 251 € 15 0Æ35 € 0Æ05 24Æ3
Mean 281 € 54 250 € 14 0Æ47 € 0Æ08 33Æ0€9 Æ1
Tick numbers and weights are the means of 18 measurements; reproductive potential the mean of 8.
Means significantly less than controls: *P <0 Æ05; **P <0 Æ01.
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Groups of six sheep were vaccinated with each of the
recombinant antigens, 5¢-nucleotidase and Bm86, or with
adjuvant alone. Within each group of six, three were vacci-
nated using ISA50 as adjuvant and three using ISA773.
Geometric mean antibody titres for the two antigens in
two adjuvants in 12 sheep are listed in Table 2. Two way
analysis of variance of log10 transformed titres using anti-
gen and adjuvant as factors showed the effect of adjuvant
to be significant (P <0 Æ01), average peak antibody titres
being 5-fold lower with ISA773. An experiment with
recombinant Bm91 antigen in the two adjuvants showed
the same disparity in mean antibody titres (P. Willadsen,
unpublished data).
Efficacies of the 5¢-nucleotidase and Bm86 vaccines
were assessed with an adult tick challenge as described in
Materials and methods using female ticks in a ring
attached to the shaved skin of sheep, and duplicate rings
on each sheep. Engorgement success was calculated rela-
tive to the number of female ticks attached 24 h after
application, rather than the number applied within each
ring initially. The number of survivors at 24 h was used
as the baseline because damage to ticks is always possible
in the process of physical removal of engorged nymphs
from their bovine host, moulting in an incubator and
re-application to sheep. However, survival and attachment
at 24 h were high, an average of 89% of the ticks applied
and there was no significant difference between ticks on
control (88%) and vaccinated sheep (92% for 5¢-nucleo-
tidase; 87% for Bm86). Therefore, accidental damage was
not important and neither was early vaccine-induced
mortality significant.
Three parameters were used to measure feeding suc-
cess: percentage of ticks completing engorgement relative
to ticks attached at 24 h; fecundity measured as mass of
eggs laid relative to the mass of engorged ticks and, as a
single, summary indicator of vaccine efficacy, the repro-
ductive potential measured as the mass of eggs laid per
10 ticks attached at 24 h. The results are listed in
Table 3. Vaccination results were analysed using a two
way ANOVA with treatment (vaccinated or control) and
adjuvant (ISA50 or ISA773) as factors, adjuvant acting
as a de facto measure of antibody titre, given the large
differences between mean antibody titres obtained with
the two adjuvants. The significance of pairwise differ-
ences between groups was examined using the Tukey
Test.
The effect of vaccination with Bm86 was significant for
all parameters (P <0 Æ01) with both adjuvants separately
and as a combined group. For the group vaccinated with
5¢-nucleotidase, the effect of adjuvant was significant for
percentage engorgement (P <0 Æ01), fecundity (P <0 Æ05)
and reproductive potential (P <0 Æ01). Despite the small
animal numbers, the effects of 5¢-nucleotidase were signifi-
cant when ISA50 was used as adjuvant. In neither the
group vaccinated using ISA773 nor in the combined group
was the effect on ticks significant. The likely explanation is
the differences in antibody titre. The probable importance
Table 2 Effects of adjuvant on geometric mean antibody titres in
sheep
Antigen
Adjuvant
Difference (fold) ISA50 ISA773
5¢-Nucleotidase 75 000 14 700 5Æ1
Bm86 62 400 12 100 5Æ2
Table 3 Vaccination of sheep with recombinant 5¢-nucleotidase and Bm86
Antigen Adjuvant
Parasitological parameters
Engorgement (%) Fecundity Reproductive potential
5¢-Nucleotidase ISA50 29Æ3( P <0 Æ01) 34Æ2 143 (P <0 Æ05)
Bm86 18Æ3( P <0 Æ01) 27Æ0( P <0 Æ05) 77 (P <0 Æ01)
Control 70Æ86 6 Æ9 526
5¢-Nucleotidase ISA773 71Æ18 4 Æ9 637
Bm86 14Æ5( P <0 Æ01) 12Æ5( P <0 Æ01) 44 (P <0 Æ01)
Control 73Æ28 8 Æ6 588
5¢-Nucleotidase Combined 50Æ35 9 Æ6 390
Bm86 16Æ4( P <0 Æ01) 19Æ8( P <0 Æ01) 61 (P <0 Æ01)
Control 73Æ27 7 Æ7 557
Where no probability is given, the difference between the vaccinated and control groups was not significant at P <0 Æ05.
Fecundity = (mass eggs laid⁄mass engorged ticks) · 100.
Reproductive potential = mass eggs laid (mg)⁄10 female ticks attached at 24 h.
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examination of the correlations between the parasite
parameters and log10 antibody titre for all sheep (Fig-
ure 1). All correlations were statistically significant
(P <0 Æ01).
Vaccination of cattle with recombinant 5¢-nucleotidase
alone and in combination with Bm86
Groups of four cattle were vaccinated with recombinant
5¢-nucleotidase, Bm86 and the two antigens in combina-
tion and challenged with a standardized infestation of
larval ticks as described in Materials and methods. The
results of parasite challenge are listed in Table 1.
The Bm86 antigen gave overall protection, measured by
the reproductive potential, of 81% with statistically signifi-
cant effects on each of the individual parameters of mean
numbers of ticks engorging, mean weight of engorged
female ticks and mean fecundity (all P <0 Æ01). In con-
trast, vaccination with 5¢-nucleotidase had no effect on
any parameter. As it is always possible that two antigens
in combination are more efficacious than either singly, the
effect of combining the antigens was also investigated. The
data in Table 1 show, however, that the dual antigen com-
bination had no advantage compared with Bm86 alone. In
fact, overall protection in the combined group was
decreased by about half compared with Bm86 alone,
although the difference was not statistically significant.
Comparative antibody responses of sheep and cattle
The fact that 5¢-nucleotidase, at least at high antibody
titres, seemed to be quite efficacious against tick infesta-
tion in sheep but completely ineffective in cattle is impor-
tant to understand. For sheep, the evidence suggests that
efficacy may correlate with antibody titre and this mirrors
the experience of large numbers of trials with the Bm86
antigen in cattle. Therefore, one obvious explanation of
the difference in protection between sheep and cattle
would be a difference in anti-nucleotidase antibody titres.
This was examined in two ways. In both experiments, the
antisera used were pools of ovine and bovine sera of peak
antibody titres. In the first experimental approach, ELI-
SAs were performed as described in Materials and meth-
ods using recombinant 5¢-nucleotidase as antigen and
Figure 1 Correlation of the antibody titre to 5¢-nucleotidase with
the mass of eggs laid per 10 female ticks attached to sheep after
24 h.
Figure 2 ELISA assays of pooled, high
titre bovine (d) and ovine ( ) sera
against recombinant 5¢-nucleotidase. The
detection reagent was peroxidase-coupled
protein G at dilutions of (from left to
right) 1 in 500; 1 in 1000 and 1 in 1500.
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bound IgG. Protein G reacts strongly with both ovine and
bovine IgG and so may minimize differences in the sensi-
tivity of species-specific second antibody reagents. Peroxi-
dase-protein G was used at three dilutions. The results are
shown in Figure 2 and suggest that there was little
difference in the titres of ovine and bovine anti-nucleotid-
ase antibodies.
In a second experimental approach, serial dilutions of
bovine anti-nucleotidase serum were made in the presence
of dilutions of ovine anti-nucleotidase ranging from
1⁄2000 to 1⁄64 000. Normal ELISAs were then performed
with these dilutions, using as a second antibody peroxi-
dase-coupled ovine anti-bovine IgG. This therefore mea-
sured the ability of an excess of ovine anti-nucleotidase to
compete with bovine antibody for bound nucleotidase. As
expected, there was no reaction of the second antibody
with ovine IgG. The results are shown in Figure 3 and
demonstrate that the competition of the ovine anti-nucleo-
tidase with the bovine equivalent was even less than
expected. For example, a 1⁄2000 dilution of ovine anti-
body reduced the binding of a 1⁄50 000 dilution of the
bovine antibody by only 12%.
DISCUSSION
Successful vaccination against the tick R. (Boophilus)
microplus has been previously achieved using the Bm86
antigen that relies on the reaction between ingested host
antibody and the antigen, which is primarily located on
the microvilli of the gut digest cells (14). The discovery of
that antigen was the result of a laborious, expensive and
time consuming process of protein fractionation, followed
by vaccination trials in cattle. Improvements in the exist-
ing vaccine are likely to rely on the discovery of other
antigens that, in combination with Bm86, offer enhanced
efficacy. The discovery of efficacious antigens, however,
remains a significant challenge. It is attractive to think
that the process could be expedited in two ways. First,
compared with the laborious process of using animal vac-
cination trials to sort through gene libraries or complex
protein extracts, the use of various forms of circumstantial
evidence to suggest proteins that might be effective anti-
gens would be rapid and cost effective, if successful. Sec-
ondly, the use of a model host for vaccination trials would
circumvent some of the expenses and constraints of cattle
vaccination. The experiments reported here attempt to
address both issues.
As summarized in the Introduction, previous research
has given a number of reasons for thinking that the 5¢-
nucleotidase could be a protective antigen. Initial trials
with recombinant 5¢-nucleotidase were carried out using
sheep as a model host. Sheep are a good host for adult
ticks and the gross biology appears to be normal i.e.
engorgement success is high and adult weights and egg
laying are normal. These vaccination trials used two adju-
vants, ISA50 and ISA773. The purpose of this was 2-fold.
Efficacy of Bm86 vaccination in cattle is strongly depen-
dent on antibody titre (19–21) as it probably is in sheep
(12) and it was of interest to induce a range of antibody
titres to 5¢-nucleotidase to see if a similar relationship
occurred. Secondly, ISA773 is a newer adjuvant with the
potential advantage of very simple formulation under
difficult field conditions, the ultimate objective of this
research.
Vaccination with the recombinant Bm86 and 5¢-nucleo-
tidase antigens showed a strong effect of Bm86 on
engorgement success and oviposition, with an overall effi-
cacy of 85%. This is consistent with earlier reports,
although the effect of vaccination was considerably weaker
in the current experiments (12). 5¢-Nucleotidase also
showed good efficacy, with an overall reduction in the
mass of eggs laid by a standard number of infesting adult
ticks of 73%. This was seen, however, only in a group with
high antibody titres. There appeared to be a significant
correlation between efficacy and antibody titre, as has
been reported for Bm86 in cattle (19).
Given the positive result of vaccination in sheep, it was
disappointing that in a subsequent trial in cattle, the
recombinant 5¢-nucleotidase antigen showed no effect. In
principle, it is still possible that an antigen, although
ineffective on its own, may be capable of enhancing the
efficacy of a combined vaccine. This is particularly the
case for an antigen capable of complementing Bm86. One
Figure 3 Log titres bovine antibody to 5¢-nucleotidase, measured
as described in Materials and methods, in the presence of varying
dilutions of ovine anti-5¢-nucleotidase. The detection reagent was
ovine anti-bovine IgG antibody coupled to peroxidase. The log
titre in the absence of any ovine antiserum was 4Æ7.
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duce destruction of tick gut cells and hence greatly
increased leakage of bovine antibody into the tick’s hae-
molymph (14). It is possible therefore that access of anti-
body to a second target, such as 5¢-nucleotidase, would be
facilitated in a dual antigen vaccine. However, there was
no evidence at all for increased efficacy of a Bm86 plus 5¢
nucleotidase vaccine compared to Bm86 alone. It is impor-
tant although that the number of examples of experimen-
tal anti-parasite vaccination where multi-antigen
formulations have actually been shown to give increased
protection is very small indeed (2).
One obvious explanation of the difference between
results with sheep and cattle would be a difference in anti-
5¢-nucleotidase antibody titre. This was examined in two
ways: by a simple comparison of ELISA titres using
labelled protein G as the detection reagent, on the
assumption that protein G would react with both ovine
and bovine IgG and secondly, in a competitive ELISA.
Neither experiment supported the idea that a difference in
bovine cf. ovine antibody was responsible for the vaccina-
tion result. While neither experiment may realistically
reflect the binding of host IgG to nucleotidase in tick tis-
sues, other explanations for the difference between tick
host species must be sought. In practical terms, the result,
combined with that reported earlier for Bm86 vaccination,
suggest that sheep will be an imperfect model host for the
development of an anti-tick vaccine in cattle.
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